About nasal polyps

Chronic sinusitis (CS) is an inflammatory condition commonly divided into 2 main subgroups: with and without nasal polyps.1 Nasal polyposis, like other phenotypes of CS, is characterized by chronic inflammation high and deep in the nasal passages.1,2

Nasal polyps are benign growths that arise from inflamed tissue.2 Evidence suggests that conditions which trigger chronic inflammation in the nose and/or nasal sinuses can promote nasal polyposis.1,3

Up to 10 million adults in the United States have nasal polyps and the associated symptoms, which can last up to 12 weeks3-5:

  • Nasal congestion or obstruction
  • Reduction or loss of sense of smell and taste
  • Facial pain/pressure
  • Rhinorrhea or postnasal drip

XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.

 

Nasal polyps reside high and deep in the nasal passages

Chronic inflammation accompanied by polypoid tissue in the middle meatus obstructs ventilation and drainage2

The ostiomeatal complex (OMC) is a region where nasal polyps usually originate and through which most sinuses drain and ventilate.6-9

  • Complexities of the nasal anatomy also make it difficult for an anti-inflammatory to reach high and deep in the nasal passages, including the OMC
  • Nasal polyps may not be visible during a routine nasal exam
Patients are frustrated due to lack of symptom relief
>80% of patients with CS with nasal polyps using an intranasal steroid (INS) reported frustration with symptom relief.10
Explore how Optinose Exhalation Delivery Systems (EDS) were designed with the nasal anatomy in mind.
References:
  1. Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(suppl 1):S22-S209.
  2. Newton JR and Ah-See, KW. A review of nasal polyposis. Ther Clin Risk Manag. 2008;4(2):507-512.
  3. Hull BP, Chandra RK. Refractory chronic rhinosinusitis with nasal polyposis. Otolaryngol Clin North Am. 2017;50(1):61-81.
  4. Djupesland PG, Vlckova I, Hewson G. Impact of baseline nasal polyp size and previous surgery on efficacy of fluticasone delivered with a novel device: A subgroup analysis. Am J Rhinol Allergy. 2010;24:291-295.
  5. Lam K, Schleimer R, Kern RC. The etiology and pathogenesis of chronic rhinosinusitis: a review of current hypotheses. Curr Allergy Asthma Rep. 2015; 15(7):41.
  6. Zhong C, Jiang Z, Zhang X. Effect of distribution of nasal polyps in ostiomeatal complex on long-term outcomes after endoscopic surgery. Eur Arch Otorhinolaryngol. 2015;272(12):3757-3762.
  7. Larsen PL, Tos M. Origin of nasal polyps: an endoscopic autopsy study. Laryngoscope. 2004;114(4):710-719.
  8. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013;3(1):42-62.
  9. Liang J, Lane AP. Topical drug delivery for chronic rhinosinusitis. Curr Otorhinolaryngol Rep. 2013;1(1):51-60.
  10. Data on file. OptiNose US, Inc.